Current Editions
If half the time spent on hysteria about China went to competing on merits, biotechs and patients would be much better served
Editor's Commentary
Why leaders of the U.S.’s biggest drug companies should use their influence to stop a ruinous proposal
Editor's Commentary
The U.S. still leads in biopharma innovation. Defensive policy alone will lose it
Guest Commentary
Product Development
KAI-4729 adds Kailera and Hengrui to a growing MASH pipeline testing whether glucagon agonism can enhance incretin therapy’s liver benefit
Data Byte
At least eight new products and three new indications await decisions
Oral Wegovy for obesity headlines 11 recommended label extensions
Discovery & Translation
BioCentury’s translational roundup also includes a method to restore tertiary lymphoid structures in lung cancer, and papers from six newcos
Politics, Policy & Law
Alkermes CEO on how policy, economics shape drug development, from the IRA to MFN and beyond
Deals
Deal for up to $1.3B accompanies new data showing efficacy signal for long-acting anti-IL-13 molecule
China-based innovator receives $650M up front, aims to co-commercialize more programs globally in wake of 2025 Takeda deal
Finance
Plus: Editas’ follow-on, Clearnote’s series D and more
Biopharma Stock Performers
Use BioCentury's interactive dashboard to view top-performing biopharma stocks for the day and the week.
Product Development
Management Tracks
BioCentury ISSN 1097-7201